

# Eden Research PLC

02:48 29 Jul 2019

## Eden Research fungicide granted 'emergency use' authorisation in France

Eden Research PLC's (LON:EDEN) fungicide, Mevalone, has been granted 120-day "emergency use" authorisation in France for the treatment of storage diseases on apples.

The biopesticide supplier's commercial partner, Sumi Agro, has been selling Mevalone in France since receiving approval for the sale and use of the product for the treatment of botrytis on table and wine grapes in January 2017.

Eden said the emergency use approval represents the first authorisation for the use of Mevalone on apples and for the treatment of post-harvest storage diseases.

### READ: Eden Research partner make first sales in Italy of breakthrough bio-pesticide

Emergency authorisations are granted in the European Union to meet the requirements of growers in the absence of suitable commercially-available alternatives.

Sumi Agro will sell Mevalone to apple producers, which will apply the fungicide just before harvest.

France is one of the top 10 producers of apples globally and is the third largest producer in Europe.

Sean Smith, chief executive of Eden, said: "This is excellent news supporting the further growth of Mevalone sales as it represents a major new use on an important crop for the treatment of diseases that affect the shelf life of apples.

"Extending the shelf life of any produce is an impactful way of helping to reduce food chain costs and food waste.

"Whist this derogation is valid until the 21st of November 2019, it is a useful illustration of the importance placed by the authorities on the introduction of new, sustainable crop protection products that meet consumer demand for safe foods that are free from pesticide residues."

Smith said the company is working actively with Sumi Agro to gain full authorisation of Mevalone for use in the treatment of pome fruit storage disease.

**Price:** 8.5

**Market Cap:** £32.33 m

### 1 Year Share Price Graph



October 2019    April 2020    October 2020

### Share Information

**Code:** EDEN

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>10.57</b>	<b>4.425</b>

**Sector:** Chemicals

**Website:** [www.edenresearch.com](http://www.edenresearch.com)

### Company Synopsis:

*Eden provides sustainable solutions for crop protection, animal health and consumer products. Like humans and animals, plants have developed defences against disease, pests and various other threats. Essential oils are one component of these defence systems and these oils contain active molecules that help fight against disease, oxidative stress and insect predators.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Eden Research PLC named herein, including the promotion by the Company of Eden Research PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).